Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice

Annals of the Rheumatic Diseases

Volumn 64, Issue 11, 2005, Pages 1550-1556

  Mukherjee, P ^b   Yang, S Y ^b   Wu, B ^b   Song, Z ^b   Myers, L K ^c   Robbins, P D ^d   Wooley, P H ^a,b  

^a HUTZEL HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COLLAGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TRANSGENE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; MICE; MICE, INBRED DBA; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, TUMOR NECROSIS FACTOR; RETROVIRIDAE; SEVERITY OF ILLNESS INDEX; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 27444440689     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.025619     Document Type: Article

References (41)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Lubberts E, Joosten LA, van Den BL, Helsen MM, Bakker AC, van Meurs JB, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546-56.
3. Wooley PH, Panayi GS, Batchelor JR. Lymphocytotoxins in rheumatoid arthritis: prevalence, lymphocyte specificity, and HLA-DR antigens. Ann Rheum Dis 1981;40:154-6.
4. Yoo TJ, Kim SY, Stuart JM, Floyd RA, Olson GA, Cremer MA, et al. Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med 1988;168:777-82.
5. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16.
6. Chu CQ, Londei M. Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J Immunol 1996;157:2685-9.
7. Chiocchia G, Boissier MC, Fournier C. Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies. Eur J Immunol 1991;21:2899-905.
8. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997;61:1861-78.
9. Myers LK, Seyer JM, Stuart JM, Terato K, David CS, Kang AH. T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J Immunol 1993;151:500-5.
10. Malmstrom V, Kjellen P, Holmdahl R. Type II collagen in cartilage evokes peptide-specific tolerance and skews the immune response. J Autoimmun 1998;11:213-21.
11. Brand DD, Myers LK, Terato K, Whittington KB, Stuart JM, Kang AH, et al. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine alpha 1(II)-CB11 in H-2q mice. J Immunol 1994;152:3088-97.
12. Osman GE, Toda M, Kanagawa O, Hood LE. Characterization of the T cell receptor repertoire causing collagen arthritis in mice. J Exp Med 1993;177:387-95.
13. Offner H, Hashim GA, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991;251:430-2.
14. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986;163:1363-75.
15. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid-arthritis - regulation by tumor-necrosis-factor-alpha. Eur J Immunol 1991;21:2575-9.
16. Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-Mutafchieva L, Buurman W, et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999;163:1000-9.
17. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci 1998;95:4613-18.
18. Peppel K, Crawford D, Beutler B. A Tumor-necrosis-factor (TNF) receptor-IgG heavy-chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
19. Kim SH, Yu SS, Park JS, Robbins PD, An CS, Kim S. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998;72:994-1004.
20. Mukherjee P, Wu B, Mayton L, Kim SH, Robbins PD, Wooley PH. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis 2003;62:707-14.
21. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor-necrosis-factor receptor Fc fusion protein on type-II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
22. Wooley PH, Schaefer C, Whalen JD, Dutcher JA, Counts DF. A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J Rheumatol 1997;24:890-8.
23. Holmdahl R, Bailey C, Enander I, Mayer R, Klareskog L, Moran T, et al. Origin of the autoreactive anti-type II collagen response. II. Specificities, antibody isotypes and usage of V gene families of anti-type II collagen B cells. J Immunol 1989;142:1881-6.
24. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
25. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
26. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatoty cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytok Netw 1995;6:225-30.
27. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, et al. Adenoviral transfer of the viral IL-IO gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999;162:3625-32.
28. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
29. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci 1992;89:7375-9.
30. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
31. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
32. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature 1997;389:239-42.
33. Ghivizzani SC, Lechman ER, Tio C, Mule KM, Chada S, McCormack JE, et al. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther 1997;4:977-82.
34. Taylor PC, Plater-Zyberk C, Maini RN. The role of the B cells in the adoptive transfer of collagen-induced arthritis from DBA/1 (H-2q) to SCID (H-2d) mice. Eur J Immunol 1995;25:763-9.
35. Moudgil KD, Chang TT, Eradat H, Chen AM, Gupta RS, Brahn E, et al. Diversification of T cell responses to carboxy-terminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis. J Exp Med 1997;185:1307-16.
36. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
37. Haqqi TM, Banerjee S, Anderson GD, David CS. RIII S/J (H-2r). An inbred mouse strain with a massive deletion of T cell receptor V beta genes. J Exp Med 1989;169:1903-9.
38. Haqqi TM, Banerjee S, Jones WL, Anderson G, Behlke MA, Loh DY, et al. Identification of T-cell receptor V beta deletion mutant mouse strain AU/ssJ (H-2q) which is resistant to collagen-induced arthritis. Immunogen 1989;29:180-5.
39. Haqqi TM, David CS. T-cell receptor V beta genes repertoire in mice. Possible role in resistance and susceptibility to type II collagen-induced arthritis. J Autoimmun 1990;3:113-21.
40. Nabozny GH, Bull MJ, Hanson J, Griffiths MM, Luthra HS, David CS. Collagen-induced arthritis in T cell receptor V beta congenic B10.Q mice. J Exp Med 1994;180:517-24.
41. Haqqi TM, Anderson GD, Banerjee S, David CS. Restricted heterogeneity in T-cell antigen receptor V beta gene usage in the lymph nodes and arthritic joints of mice. Proc Natl Acad Sci 1992;89:1253-5.